McNicoll Lewis & Vlak Starts Sunesis Pharmaceuticals (SNSS) at Buy; Vosaroxin in Pivotal Phase III AML Trial – StreetInsider.com

PT $3.50. MLV analyst said, “The company’s lead drug candidate, vosaroxin, is a quinolone derivative currently being evaluated in a pivotal Phase III trial called VALOR for the treatment of relapsed and refractory acute myeloid leukemia (AML)…